Approved indications: Bafiertam is an oral disease-modifying therapy for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease.

Off-label uses: There are no well-established off-label uses for Bafiertam; in routine practice it is generally reserved for its approved multiple sclerosis indications, even though other fumarate formulations are used for conditions such as psoriasis.

Efficacy expectations:

• Approval is based on data with dimethyl fumarate, which produces the same active metabolite; in large trials of dimethyl fumarate, annual relapse rates were reduced by roughly 40–50% versus placebo and MRI scans showed fewer new or enlarging lesions.
• Benefits build over time: protection from relapses and new MRI activity is usually assessed over several months, with full effect typically judged after 6–12 months of continuous treatment.
• Compared with other oral MS therapies, Bafiertam offers moderate-to-high efficacy; some infusion therapies may suppress disease activity more strongly but often require more intensive monitoring and carry higher risks.

Typical dosing: For adults with relapsing multiple sclerosis, the usual schedule is 95 mg by mouth twice daily for 7 days, then 190 mg (two 95-mg capsules) twice daily as a maintenance dose; if the maintenance dose is not tolerated, a temporary reduction back to 95 mg twice daily may be used, with a goal of returning to 190 mg twice daily within about 4 weeks.

How to take it: Swallow the delayed-release capsules whole and intact with water; do not crush, chew, or open them or mix the contents with food. Bafiertam can be taken with or without food and has no specific dietary or alcohol restrictions, although heavy alcohol use should be avoided because it can increase liver risk.

Special dosing instructions and monitoring: Before starting Bafiertam, blood tests should check a complete blood count (including lymphocyte count) and liver function; a CBC is typically repeated about 6 months after starting and then every 6–12 months, with liver tests as clinically indicated. Bafiertam must not be used together with dimethyl fumarate (Tecfidera) or diroximel fumarate (Vumerity), since these share the same active component.

Missed dose: If you miss a dose, take it as soon as you remember unless it is almost time for your next scheduled dose; if it is close to the next dose, skip the missed dose and resume your regular schedule, and do not take two doses at once.

Overdose: In case of suspected overdose, contact emergency medical services or a poison control center right away.

Common side effects:

• Flushing (warmth, redness, itching, or rash) is very common, especially soon after a dose, and is usually mild-to-moderate and tends to lessen over time.
• Stomach problems such as abdominal pain, nausea, vomiting, diarrhea, or indigestion often occur in the first weeks of therapy and frequently improve with continued use.
• Your prescriber may suggest taking a non–enteric-coated aspirin (up to 325 mg) about 30 minutes before a dose to reduce flushing, if appropriate for you.

Serious or rare adverse effects (seek urgent medical help):

• Severe allergic reactions, including hives, trouble breathing, or swelling of the face, lips, tongue, or throat.
• Signs of a rare brain infection called PML (progressive multifocal leukoencephalopathy), such as new or worsening problems with vision, thinking, memory, speech, balance, or strength.
• Symptoms of serious infection, including shingles (herpes zoster), high fever, chills, confusion, severe or persistent diarrhea, or other unusual infections.
• Signs of liver injury, such as severe fatigue, loss of appetite, pain in the upper right abdomen, dark urine, or yellowing of the skin or eyes.
• Severe or persistent gastrointestinal symptoms suggesting bleeding or injury (black or bloody stools, vomiting blood or material that looks like coffee grounds, or strong stomach pain that does not go away).

Warnings and precautions: Bafiertam can lower lymphocyte (white blood cell) counts and increase infection risk, so it should be used cautiously in people with weakened immune systems or current infections. It may cause liver injury and serious gastrointestinal problems in some patients. Its safety is not established in children under 18 years; in pregnancy or breastfeeding, use is generally considered only if the potential benefit justifies possible risks. Tell your clinician about liver disease, past low white blood cell counts, serious stomach or bowel disease, and all other medicines you take, especially other immunosuppressive or MS therapies.

Safety compared with other MS drugs: Fumarate medicines like Bafiertam have an established safety profile as oral MS treatments but still require regular blood tests and monitoring for PML, serious infections, lymphopenia, and liver injury; they often have more systemic risks than older injectable MS drugs but may have fewer intensive safety requirements than some high-efficacy infusion therapies.

Reporting side effects and safety updates: Side effects can be reported to the FDA MedWatch program (for example at 1-800-FDA-1088) or to the manufacturer, and up-to-date safety information is provided through the Medication Guide, prescribing information, and FDA safety communications.

Prescription and OTC drug interactions: Do not take Bafiertam with dimethyl fumarate or diroximel fumarate. Use caution and close medical supervision if it is combined with other medicines that weaken the immune system or lower white blood cell counts (such as some chemotherapy agents, biologic drugs, long-term corticosteroids, or other MS disease-modifying therapies), because this may further increase infection risk. There are no major known interactions through common liver enzyme pathways, but all prescription, over-the-counter, and herbal products should be reviewed by your clinician or pharmacist.

Food, alcohol, and supplements: Bafiertam can be taken with or without food and has no specific food restrictions. Alcohol is not strictly contraindicated, but heavy or chronic drinking can add to the risk of liver problems and should be avoided. Be cautious with herbal or dietary supplements marketed to strongly affect the immune system, since their combined impact with Bafiertam has not been well studied.

Conditions and co-medications requiring extra caution: Tell your clinician if you have or have had liver disease, chronic or recurrent infections, low white blood cell counts, serious gastrointestinal disease, kidney disease, or if you are pregnant, planning pregnancy, or breastfeeding. These conditions may alter the risk–benefit balance, the choice of MS therapy, or the intensity of monitoring.

Monitoring needs: Routine monitoring usually includes CBC with lymphocyte count and liver function tests before starting Bafiertam, again at about 6 months, and every 6–12 months thereafter, with more frequent testing if counts are low, liver tests are abnormal, or infections occur. Neurologic examinations and periodic MRI scans are often used to track MS disease activity while you are on treatment.

Q: What is Bafiertam and what does it treat?
A: Bafiertam (monomethyl fumarate) is an oral disease-modifying medicine for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease.

Q: How long does it take for Bafiertam to start working?
A: You may not feel an immediate change, because Bafiertam’s main goal is to reduce future relapses and new MRI lesions; its benefits are usually judged over several months, with full effect typically assessed after 6–12 months of continuous use.

Q: What can I do about flushing and stomach upset?
A: These reactions are common early in treatment and often improve over time; taking doses with food, staying cool during flushing episodes, and, in some cases, using a non–enteric-coated aspirin before dosing if your prescriber recommends it may help reduce these symptoms.

Q: Can I drink alcohol while taking Bafiertam?
A: Occasional light-to-moderate alcohol use is generally permitted, but heavy or frequent drinking should be avoided because it can increase the risk of liver problems when combined with Bafiertam.

Q: Do I need regular blood tests while on Bafiertam?
A: Yes; typical monitoring includes a complete blood count (with lymphocyte count) and liver function tests before starting, again about 6 months after beginning therapy, and then every 6–12 months or as your clinician advises.

Q: How should I store Bafiertam, especially after I open the bottle?
A: Keep unopened bottles refrigerated (not frozen) in their original container; after opening, store the bottle at room temperature (68°F–77°F or 20°C–25°C), protected from heat and light, and discard any remaining capsules 3 months after first opening.

Storage (unopened bottle): Store in a refrigerator at 35°F–46°F (2°C–8°C); do not freeze, keep the bottle in its original container, and protect it from light.

Storage (after opening): Keep the opened bottle at room temperature 68°F–77°F (20°C–25°C), away from heat and moisture, in the original light-protective container; capsules are usable for up to 3 months after first opening, then any remaining should be thrown away.

General handling: Keep Bafiertam out of the reach of children and pets, and avoid storing it in very hot places since the capsules may become deformed at high temperatures.

Disposal: Prefer a pharmacy or community drug take-back program; if none is available, remove capsules from the bottle, mix them with an undesirable substance (like used coffee grounds or cat litter), seal in a container or bag, and place in household trash—do not flush capsules down the toilet unless specifically instructed.